Relationship of cytokine level dynamics with longterm results of early rheumatoid arthritis therapy
https://doi.org/10.47360/1995-4484-2022-72-79
Abstract
The aim of the work – to research the relationship between the dynamics of cytokine levels in the early period (the first 12 and 24 weeks) of pharmacotherapy for rheumatoid arthritis (RA) and long-term outcomes in patients with the disease.
Material and methods. The analysis included 93 patients with early RA. The majority of patients were women (n=77), middle-aged (58 [49; 66] years), with an early stage of the disease (the duration of the disease is 7 [4–11.5] months), seropositive according to IgM rheumatoid factor and cyclic citrullinated peptide antibodies, who had high (59.7%) or moderate (38.8%) disease activity.
The concentration of 27 cytokines in the blood serum was determined with the help of multiplex xMAP technology on the Bio-Plex array system analyzer (BIORAD, USA). Repeated clinical examination of patients was carried out after 6 years.
Results. Patients who achieved remission/low disease activity SDAI after 6 years had a lower level of IL-6 (7.7 [7.4; 23.3]), IL-9 (13.5 [9.1; 18.9]) 12 weeks after the start of therapy; lower IL-9 level (12.6 [6.8; 16.2]) 24 weeks after the start of the treatment, compared with the group of patients with moderate and high inflammatory activity (23.5 [12.4; 69.5], 17.8 [15; 29] and 18.5 [14.2; 22.8] respectively).
Findings. The assessment of the level of proinflammatory cytokines (IL-6, IL-17), immunoregulatory cytokine IL-9 allows to evaluate the activity of the disease more fully and identify a group of patients, who needs the therapy intensification.
About the Authors
V. V. Rybakova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Valeriya Rybakova
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
нет
A. S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Anastasia S. Avdeeva
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
нет
D. A. Dibrov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Danil A. Dibrov
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
нет
Е. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Evgeny L. Nasonov
115522, Moscow, Kashirskoye Highway, 34A
119991, Moscow, Trubetskaya str., 8, building 2
Competing Interests:
нет
References
1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi: 10.1038/nrdp.2018.1
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637. doi: 10.1136/ard.2009.123919
3. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: Russian and international guidelines. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(5):557-571 (In Russ.). doi: 10.14412/1995-4484-2016-557-571
4. Aletaha D. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020;110:102405. doi: 10.1016/j.jaut.2020.102405
5. Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: Systematic reviews. Health Technol Assess. 2018;22(66):1-294. doi: 10.3310/hta22660
6. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(3):263-271 (In Russ.). doi: 10.14412/1995-4484-2018-263-271
7. Wu X, Sheng X, Sheng R, Lu H, Xu H. Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis. Front Med. 2019;13(4):411-419. doi: 10.1007/s11684-018-0659-3
8. Takeuchi T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin Immunol. 2018;186:59-62. doi: 10.1016/j.clim.2017.07.019
9. Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: Strategies for the 3-month time point. Ann Rheum Dis. 2016;75(8):1479-1485. doi: 10.1136/annrheumdis-2015-208324
10. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226-3235. doi: 10.1002/art.22943
11. Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502
12. van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trial. J Rheumatol. 2012;39(7):1326-1333. doi: 10.3899/jrheum.111171
13. Schipper L, Fransen J, Den Broeder A, Riel P. Time to achieve remission determines to be in remission. Arthritis Res Ther. 2010;12:97. doi: 10.1186/ar3027
14. Akdemir G, Heimans L, Bergstra SA, Goekoop RJ, van Oosterhout M, van Groenendael JHLM, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann Rheum Dis. 2018;77(1):111-118. doi: 10.1136/annrheumdis-2017-211375
15. Verstappen M, Niemantsverdriet E, Matthijssen XME, le Cessie S, van der Helm-van Mil AHM. Early DAS response after DMARDstart increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):276. doi: 10.1186/s13075-020-02368-9
16. Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012;71(2):206-212. doi: 10.1136/ard.2011.153551
17. Nasonov EL, Karateev DE, Satybaldyev AM, Luchikhina EL, Lukina GV, Nikolenko MV, et al. Rheumatoid arthritis in the Russian Federation according to Russian arthritis registry data (communication I). NauchcnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(5):472-484 (In Russ.). doi: 10.14412/1995-4484-2015-472-484
18. Karateev DE, Luchikhina EL, Demidova NV, Gridneva GS, Lukina GV, Kanonirova MA, et al. Use of subcutaneous methotrexate for the treatment of patients with active rheumatoid arthritis: The REMARCA trial. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(2):138-144 (In Russ.). doi: 10.14412/1995-4484-2016-138-144
19. Rybakova VV, Avdeeva AS, Dibrov DA, Nasonov EL. The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry). Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):269-274 (In Russ.). doi: 10.47360/1995-4484-2021-269-274
20. Rybakova V, Avdeeva A, Olyunin Y, Nasonov E. Long-term results of T2T therapy initiated at the onset of rheumatoid arthritis (data from OREL registry). Ann Rheum Dis. 2021;80:1134. doi: 10.1136/annrheumdis-2021-eular.1552
21. Novikov AA, Aleksandrova EN, Nasonov EL. Elaboration and application of the diagnostic index based on multivariate analysis of biomarkers to determine the activity of rheumatoid arthritis. NauchcnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(1):72-78 (In Russ.). doi: 10.14412/1995-4484-2014-72-78
22. Avdeeva AS, Novikov AA, Aleksandrova EN, Karateev DE, Luchikhina EL, Nasonov EL. Changes of cytokine levels during therapy with methotrexate and adalimumab in patients with early rheumatoid arthritis (REMARCA study). Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(3):254-262 (In Russ.). doi: 10.14412/1995-4484-2014-254-262
23. Avdeeva AS, Novikov AA, Aleksandrova EN, Karateev DE, Smirnov AV, Luchikhina EL, et al. An association of cytokine levels with disease activity, autoantibody levels, and joint destructive changes in early rheumatoid arthritis. NauchcnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(4):385-390 (In Russ.). doi: 10.14412/1995-4484-2015-385-390
24. Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(4):584-592.
25. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:545493. doi: 10.1155/2014/545493
26. Luedders BA, Johnson TM, Sayles H, Thiele GM, Mikuls TR, O’Dell JR, et al. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. Semin Arthritis Rheum. 2020;50(5):1058-1063. doi: 10.1016/j.semarthrit.2020.05.019
27. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From clinical significance to quantification. Adv Sci (Weinh). 2021;8(15):2004433. doi: 10.1002/advs.202004433
28. Laborde CM, Castro-Santos P, Díaz-Peña R. Contribution of multiplex immunoassays to rheumatoid arthritis management: From biomarker discovery to personalized medicine. J Pers Med. 2020;10(4):202. doi: 10.3390/jpm10040202
29. Li S, Song G, Bai Y, Song N, Zhao J, Liu J, et al. Applications of protein microarrays in biomarker discovery for autoimmune diseases. Front Immunol. 2021;12:645632. doi: 10.3389/fimmu.2021.645632
30. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584
31. Nasonov EL (ed.). Rheumatology. Clinical recommendations. Moscow:GEOTARMedia;2010 (In Russ.).
32. Karateev DE, Luchikhina EL, Muravyev YuV, Demidova NV, Grineva GI, Novikova DS, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(2):117-125 (In Russ.). doi: 10.14412/1995-4484-2013-637
33. Karateev DE, Luchikhina EL, Demidova NV, Gridneva GS, Kanonirova MA, Muravyev YuV, et al. The first russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trial): Results of 12-month treatment in 130 patients. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(6):607-614 (In Russ.). doi: 10.14412/1995-4484-2014-607-614
34. Romão VC, Vital EM, Fonseca JE, Buch MH. Right drug, right patient, right time: Aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017;19(1):239. doi: 10.1186/s13075-017-1445-3
35. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013;9(5):267-276. doi: 10.1038/nrrheum.2013.14
36. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018;30(2):207-214. doi: 10.1097/BOR.0000000000000470
37. Avdeeva AS. IFN-γ-induced protein 10 (IP-10) in rheumatoid arthritis: Literature review and the authors’ own data. NauchcnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):655-661 (In Russ.). doi: 10.14412/1995-4484-2017-655-661
38. Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461
39. Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.). doi: 10.14412/1995-4484-2017-68-86
40. Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: Achievements, prospects, and hopes. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):590-599 (In Russ.). doi: 10.14412/1995-4484-2017-590-599
41. Taams LS. Interleukin-17 in rheumatoid arthritis: Trials and tribulations. J Exp Med. 2020;217(3):e20192048. doi: 10.1084/jem.20192048
42. Takeuchi T, Yoshida H, Tanaka S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmun Rev. 2021;20(9):102884. doi: 10.1016/j.autrev.2021.102884
43. Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, La Manna MP, et al. Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2015;54(12):2264-2272. doi: 10.1093/rheumatology/kev252
44. Straub RH, Müller-Ladner U, Lichtinger T, Schölmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol. 1997;36(12):1298-1303. doi: 10.1093/rheumatology/36.12.1298
45. Ma MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):158. doi: 10.1186/s13075-020-02240-w
46. Aizu M, Mizushima I, Nakazaki S, Nakashima A, Kato T, Murayama T, et al. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis. Mod Rheumatol. 2018;28(4):592-598. doi: 10.1080/14397595.2017.1370766
47. Shi R, Chen M, Litifu B. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol. 2018;28(1):126-132. doi: 10.1080/14397595.2017.1317384
48. Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, et al. Association of high serum interleukin-6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis. Arthritis Rheumatol. 2020;72(9):1456-1466. doi: 10.1002/art.41299
49. Rajaei E, Mowla K, Hayati Q, Ghorbani A, Dargahi-Malamir M, Hesam S, et al. Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity. Curr Rheumatol Rev. 2020;16(3):249-255. doi: 10.2174/1573397115666190206144223
50. Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol. 2013;32(11):1661-1666. doi: 10.1007/s10067-013-2309-0
51. Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7(7):e40362. doi: 10.1371/journal.pone.0040362
52. Hayashi S, Suzuki K, Yoshimoto K, Takeshita M, Kurasawa T, Yamaoka K, et al. Early prognostic factors associated with the efficacy of infliximab treatment for patients with rheumatoid arthritis with inadequate response to methotrexate. Rheumatol Ther. 2016;3(1):155-166. doi: 10.1007/s40744-015-0022-y
53. Takasugi K, Nishida K, Natsumeda M, Yamashita M, Yamamoto W, Ezawa K. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis. Mod Rheumatol. 2018;28(3):452-460. doi: 10.1080/14397595.2017.1361802
54. Gottenberg JE, Dayer JM, Lukas C, Ducot B, Chiocchia G, Cantagrel A, et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: Results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(7):1243-1248. doi: 10.1136/annrheumdis-2011-200975
55. Baillet A, Gossec L, Paternotte S, Etcheto A, Combe B, Meyer O, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: Results from a French national multicenter cohort. Arthritis Care Res (Hoboken). 2015;67(7):905-912. doi: 10.1002/acr.22513
56. Alekseeva OG, Novikov AA, Severinova MV, Avdeeva AS, Aleksandrova EN, Luchikhina EI, et al. The time course of changes in biomarker levels and the ultrasonic signs of inflammation in patients with rheumatoid arthritis. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(5):485-492 (In Russ.). doi: 10.14412/1995-4484-2015-485-492
57. Kondo Y, Kaneko Y, Sugiura H, Matsumoto S, Nishina N, Kuwana M, et al. Pre-treatment interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients. Rheumatology (Oxford). 2017;56(7):1089-1094. doi: 10.1093/rheumatology/kex046
58. van Hamburg JP, Tas SW. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. J Autoimmun. 2018;87:69-81. doi: 10.1016/j.jaut.2017.12.006
59. Zhang B, Jiang W. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients. Inflammopharmacology. 2019;27(6):1123-1130. doi: 10.1007/s10787-019-00624-2
60. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2011;13(4):R126. doi: 10.1186/ar3431
61. McDonald S, Reed R, Baricevic-Jones I; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; Ling S, Plant D, et al. Can serum interleukin-17 and interleukin-10 levels predict response to biologic treatments in patients with rheumatoid arthritis? Rheumatology (Oxford). 2019;58(10):1872-1873. doi: 10.1093/rheumatology/kez147
62. Sikorska D, Rutkowski R, Łuczak J, Samborski W, Witowski J. No effect of anti-TNF-α treatment on serum IL-17 in patients with rheumatoid arthritis. Cent Eur J Immunol. 2018;43(3):270-275. doi: 10.5114/ceji.2018.80045
63. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71(10):1741-1748. doi: 10.1136/annrheumdis-2011-201024
64. Lee SJ, Park W, Park SH, Shim SC, Baek HJ, Yoo DH, et al. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res. 2015;2015:487230. doi: 10.1155/2015/487230
65. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(10):562. doi: 10.1038/nrrheum.2015.128
66. Coutant F, Miossec P. Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Curr Opin Rheumatol. 2020;32(1):57-63. doi: 10.1097/BOR.0000000000000664
67. Han BK, Kuzin I, Gaughan JP, Olsen NJ, Bottaro A. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: A pilot, prospective study. Arthritis Res Ther. 2016;18:93. doi: 10.1186/s13075-016-0995-0
68. Eriksson C, Rantapää-Dahlqvist S, Sundqvist KG. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42(4):260-265. doi: 10.3109/03009742.2012.754937
69. Yukawa K, Mokuda S, Kohno H, Oi K, Kuranobu T, Tokunaga T, et al. Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(5):956-963.
70. van Hooij A, Boeters DM, Tjon Kon Fat EM, van den Eeden SJF, Corstjens PLAM, van der Helm-van Mil AHM, et al. Longitudinal IP-10 serum levels are associated with the course of disease activity and remission in patients with rheumatoid arthritis. Clin Vaccine Immunol. 2017;24(8):e00060-17. doi: 10.1128/CVI.00060-17
71. Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67(1):28-38. doi: 10.1002/art.38904
72. Dantas AT, Marques CD, da Rocha Junior LF, Cavalcanti MB, Gonçalves SM, Cardoso PR, et al. Increased serum interleukin-9 levels in rheumatoid arthritis and systemic lupus erythematosus: Pathogenic role or just an epiphenomenon? Dis Markers. 2015;2015:519638. doi: 10.1155/2015/519638
73. Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med. 2017;23(8):938-944. doi: 10.1038/nm.4373
Review
For citations:
Rybakova V.V., Avdeeva A.S., Dibrov D.A., Nasonov Е.L. Relationship of cytokine level dynamics with longterm results of early rheumatoid arthritis therapy. Rheumatology Science and Practice. 2022;60(1):72–79. (In Russ.) https://doi.org/10.47360/1995-4484-2022-72-79
Views:
390
Email this article 